Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/47481
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBansback, N.-
dc.contributor.authorWard, S.-
dc.contributor.authorKarnon, J.-
dc.date.issued2004-
dc.identifier.citationEuropean Journal of Health Economics, 2004; 5(2):188-189-
dc.identifier.issn1618-7598-
dc.identifier.issn1618-7601-
dc.identifier.urihttp://hdl.handle.net/2440/47481-
dc.descriptionThe original publication can be found at www.springerlink.com-
dc.description.statementofresponsibilityNick Bansback, Sue Ward and Jon Karnon-
dc.language.isoen-
dc.publisherSpringer-
dc.source.urihttp://springerlink.metapress.com/content/3m7uurmtclxf60n5/-
dc.subjectGemcitabine-
dc.subjectEconomic evaluation-
dc.subjectExpected value of information-
dc.title“Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK”: How important is quality of life?-
dc.typeJournal article-
dc.provenancePublished online: 27 February 2004-
dc.identifier.doi10.1007/s10198-004-0226-5-
pubs.publication-statusPublished-
dc.identifier.orcidKarnon, J. [0000-0003-3220-2099]-
Appears in Collections:Aurora harvest
Public Health publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.